A modified murine model of systemic sclerosis: Bleomycin given by pump infusion induced skin and pulmonary inflammation and fibrosis

Laboratory Investigation

Volumn 95, Issue 3, 2015, Pages 342-350

  Liang, Minrui ^a   Lv, Jiaoyan ^a   Zou, Linlin ^a   Yang, Wei ^a   Xiong, Yingluo ^a   Chen, Xiangjun ^a   Guan, Ming ^a   He, Rui ^a   Zou, Hejian ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CD3 ANTIGEN; CD45 ANTIGEN; COLLAGEN; CXCL2 CHEMOKINE; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 22; INTERLEUKIN 4; THYMUS AND ACTIVATION REGULATED CHEMOKINE; ANTINEOPLASTIC ANTIBIOTIC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CELL COUNT; CONTROLLED STUDY; CYTOARCHITECTURE; DERMATITIS; HISTOPATHOLOGY; IMMUNOPATHOLOGY; INFLAMMATORY INFILTRATE; LUNG FIBROSIS; MACROPHAGE; MOUSE; MYOFIBROBLAST; NEUTROPHIL; NONHUMAN; OSMOTIC MINIPUMP; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE; UPREGULATION; WILD TYPE; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; GENE EXPRESSION; GENETICS; HUMAN; INFUSION PUMP; LEUKOCYTE; METABOLISM; PATHOLOGY; TIME;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; CHEMOKINE CXCL2; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HUMANS; INFUSION PUMPS, IMPLANTABLE; INTERLEUKIN-1BETA; INTERLEUKIN-4; LEUKOCYTES; MACROPHAGES; MICE, INBRED C57BL; PNEUMONIA; PULMONARY FIBROSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SCLERODERMA, SYSTEMIC; T-LYMPHOCYTES; TIME FACTORS;

EID: 84928618336     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2014.145     Document Type: Article

References (33)

1. Hussein MR, Hassan HI, Hofny ER, et al. Alterations of mononuclear inflammatory cells, CD4/CD8+ T cells, interleukin 1beta, and tumour necrosis factor alpha in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis. J Clin Pathol 2005;58:178-184.
2. Deleuran B, Abraham DJ. Possible implication of the effector CD4+ T-cell subpopulation TH17 in the pathogenesis of systemic scleroderma. Nat Clin Pract Rheumatol 2007;3:682-683.
3. Kurasawa K, Hirose K, Sano H, et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000;43:2455-2463.
4. Murata M, Fujimoto M, Matsushita T, et al. Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease? J Dermatol Sci 2008;50:240-242.
5. Mathian A, Parizot C, Dorgham K, et al. Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions. Ann Rheum Dis 2012;71: 1227-1234.
6. Truchetet ME, Brembilla NC, Montanari E, et al. Interleukin-17A+cell counts are increased in systemic sclerosis skin and their number is inversely correlated with the extent of skin involvement. Arthritis Rheum 2013;65:1347-1356.
7. Gerber EE, Gallo EM, Fontana SC, et al. Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma. Nature 2013;503:126-130.
8. Hinchcliff M, Huang CC, Wood TA, et al. Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis. J Invest Dermatol 2013;133: 1979-1989.
9. Yamamoto T, Takagawa S, Katayama I, et al. Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999;112:456-462.
10. Akhmetshina A, Dees C, Busch N, et al. The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis Rheum 2009;60:1129-1136.
11. Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scalE. J ClinPathol 1988;41:467-470.
12. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004;4:583-594.
13. Marcos V, Zhou Z, Yildirim AO, et al. CXCR2 mediates NADPH oxidaseindependent neutrophil extracellular trap formation in cystic fibrosis airway inflammation. Nat Med 2010;16:1018-1023.
14. De Filippo K, Dudeck A, Hasenberg M, et al. Mast cell and macrophage chemokines CXCL1/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation. Blood 2013;121:4930-4937.
15. Kusumoto M, Xu BH, Shi MY, et al. Expression of chemokine receptor CCR4 and its ligands (CCL17 and CCL22) in murine contact hypersensitivity. J Interferon Cytok Res 2007;27:901-910.
16. Mariani M, Lang R, Binda E, et al. Dominance of CCL22 over CCL17 in induction of chemokine receptor CCR4 desensitization and internalization on human Th2 cells. Eur J Immunol 2004;34:231-240.
17. Prescott RJ, Freemont AJ, Jones CJ, et al. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992;166:255-263.
18. Kalogerou A, Gelou E, Mountantonakis S, et al. Early T cell activation in the skin from patients with systemic sclerosis. Ann Rheum Dis 2005;64:1233-1235.
19. Lee R, Reese C, Bonner M, et al. Bleomycin delivery by osmotic minipump: similarity to human scleroderma interstitial lung disease. Am J Physiol Lung Cell Mol Physiol 2014;306:L736-L748.
20. Harrison Jr. JH, Lazo JS. High dose continuous infusion of bleomycin in mice: a new model for drug-induced pulmonary fibrosis. J Pharmacol Exp Ther 1987;243:1185-1194.
21. Lazo JS, Humphreys CJ, LACK OF. Metabolism as the biochemical basis of bleomycin-induced pulmonary toxicity. Proc Natl Acad Sci USA 1983;80:3064-3068.
22. King Jr. TE, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011;378:1949-1961.
23. Belperio JA, Dy M, Burdick MD, et al. Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Resp Cell Mol Biol 2002;27:419-427.
24. Ishikawa O, Ishikawa H. Macrophage infiltration in the skin of patients with systemic-sclerosis. J Rheum 1992;19:1202-1206.
25. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003;3:23-35.
26. Mosser DM. The many faces of macrophage activation. J Leuk Biol 2003;73:209-212.
27. Raesl G, Beschinl A, Ghassabeh GH, et al. Alternatively activated macrophages in protozoan infections. Curr Opin Immunol 2007;19: 454-459.
28. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011;11:723-737.
29. Higashi-Kuwata N, Makino T, Inoue Y, et al. Alternatively activated macrophages (M2 macrophages) in the skin of patient with localized scleroderma. Exp Dermatol 2009;18:727-729.
30. Barnes TC, Spiller DG, Anderson ME, et al. Endothelial activation and apoptosis mediated by neutrophil-dependent interleukin 6 transsignalling: a novel target for systemic sclerosis? Ann Rheum Dis 2011;70:366-372.
31. Czirjak L, Danko K, Sipka S, et al. Polymorphonuclear neutrophil function in systemic sclerosis. Ann Rheum Dis 1987;46:302-306.
32. Barnes TC, Anderson ME, Edwards SW, et al. Neutrophil-derived reactive oxygen species in SSc. Rheumatology (Oxford) 2012;51: 1166-1169.
33. Maugeri N, Rovere-Querini P, Baldini M, et al. Oxidative stress elicits platelet/leukocyte inflammatory interactions via HMGB1: a candidate for microvessel injury in sytemic sclerosis. Antioxid Redox Signal 2014;20:1060-1074.